Impact of APOE status on cognitive maintenance in healthy elderly persons

International Journal of Geriatric Psychiatry

Volumn 24, Issue 2, 2009, Pages 132-141

  Zehnder, Antoinette E ^a   Bläsi, Stefan ^a   Berres, Manfred ^b   Monsch, Andreas U ^a   Stähelin, Hannes B ^a   Spiegel, René ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF APPLIED SCIENCES KOBLENZ   (Germany)

Author keywords

ApoE; CERAD; Change scores; CVLT; Practice effects

Indexed keywords

APOLIPOPROTEIN E4;

AGED; ARTICLE; COGNITION; CONTROLLED STUDY; DEMENTIA; EPISODIC MEMORY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST; WORD LIST RECALL;

AGED; AGING; ALLELES; APOLIPOPROTEINS E; COGNITION DISORDERS; EDUCATIONAL STATUS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LONGITUDINAL STUDIES; MALE; MEMORY DISORDERS; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PHENOTYPE; REGRESSION ANALYSIS;

EID: 67649372869     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2080     Document Type: Article

References (46)

1. Aebi C. 2002. Validierung der Neuropsychologischen Testbatterie CERAD-NP: Eine Multi-Center Studie. PhD-Thesis at the University of Basel, Switzerland.
2. Bathum L, Christiansen L, Jeune B, et al. 2006. Apolipoprotein E Genotypes: relationship to Cognitive Functioning, Cognitive Decline, and Survival in Nonagenarians. JAGS 54: 654-658.
3. Baxter LC, Caselli RJ, Johnson SC, et al. 2003. Apolipoprotein E ε4 affects new learning in cognitively normal individuals at risk for Alzheimer's disease. Neurobiol Aging 24: 947-952.
4. Berres M, Zehnder A, Blaäsi S, Monsch AU. 2008. Evaluation of diagnostic scores with adjustment for covariates. Stat Med. 27(10): 1777-1790.
5. Blacker D, Haines JL, Rodes L, et al. 1997. The apoE4 and age at onset of Alzheimer's disease - the NIMH genetics initiative. Neurology 48: 139-147.
6. Bondi MW, Salmon DP, Galasko D, et al. 1999. Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease. Psychol Aging 14: 295-303.
7. Bookheimer SY, Strojwas MH, Cohen MS, et al. 2000. Patterns of brain activation in people at risk for Alzheimer's disease. N. Engl J Med 343: 450-456.
8. Bretsky PM, Buckwalter JG, Seeman TE, et al. 1999. Evidence for an interaction between apolipoprotein E genotype, gender and Alzheimer's disease. Alzheimer Dis Assoc Disord 13: 216-221.
9. Bretsky P, Guralnik JM, Launer L, et al. 2003. The role of APOEepsilon4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. Neurology 60: 1077-1081.
10. Caselli RJ, Reiman EM, Osborne D, et al. 2004. Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. Neurology 62: 1990-1995.
11. Christensen H, Mackinnon AJ, Korten A, Jorm AF. 2001. The common cause hypothesis of cognitive aging: evidence for not only a common factor but also specific associations of age with vision and grip strength in a cross-sectional analysis. Psychol Aging 16: 588-599.
12. Collie A, Maruff P, Darby DG, McStephen M. 2003. The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc 9: 419-428.
13. Deary IJ, Whiteman MC, Alison P, et al. 2004. Apolipoprotein E gene variability and cognitive functions at age 79: a follow-up of the Scottish Mental Survey of 1932. Psychol Aging 19: 367-371.
14. Delis DC, Freeland J, Kramer JH, Kaplan E. 1988. Integrating Clinical Assessment with Cognitive Neuroscience: Construct Validation of the California Verbal Learning Test. J Consult Clin Psychol 56: 123-130.
15. Delis DC, Kramer JH, Kaplan E, Ober BA. 1987. California Verbal Learning Test. The Psychological Corporation: San Antonio, TX.
16. Dik MG, Jonker C, Bouter LM, et al. 2000. APOE-epsilon4 is associated with memory decline in cognitively impaired elderly. Neurology 54: 1492-1497.
17. Farrer LA, Cupples LA, Haines JL, et al. 1997. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzeheimer disease, a meta-analysis. JAMA 278: 1349-1356.
18. Fillenbaum GG, Landerman LR, Blazer DG, et al. 2001. The Relationship of APOE genotype to cognitive functioning in older African-American and Caucasian community residents. J Am Geriatr Soc 49: 1148-1155.
19. Folstein MF, Folstein SE, McHugh PR. 1975. 'Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198.
20. Glymour MM. 2007. When bad genes look good - APOE*E4, cognitive decline, and diagnostic thresholds. Am J Epidemiol 165(11): 1239-1246.
21. Growdon JH, Locascio JJ, Corkin S, et al. 1996. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology 47: 444-448.
22. Ilmberger J. 1988. Münchner Verbaler Gedächtnistest. Institut für Medizinische Psychologie: München.
23. Ivnik RJ, Smith GE, Lucas JA, et al. 1999. Testing normal older people three or four times at 1- to 2-year intervals: defining normal variance. Neuropsychol 13: 121-127.
24. Juva K, Verkkoniemi A, Viramo P, et al. 2000. APOE e4 does not predict mortality, cognitive decline, or dementia in the oldest old. Neurology 54(2): 412-415.
25. Kim KW, Youn JC, Jhoo JH, et al. 2002. Apolipoprotein E e4 allele is not associated with the cognitive impairment in communitydwelling normal elderly individuals. Int J Geriatr Psychiatry 17: 635-640.
26. Kühner C. 1997. Fragebogen zur Depressionsdiagnostik nach DSMIV (FDD - DSM - IV). Hogrefe: Göttingen.
27. Lehtovirta M, Laakso MP, Frisoni GB, Soininen H. 2000. How does the apolipoprotein E genotype modulate the brain in aging and in Alzheimer's disease? A review of neuroimaging studies. Neurobiol Aging 21: 293-300.
28. Mahley RW, Weisgraber KH, Huang Y. 2006. Apolipoprotein. E4: a causative factor and therapeutic target in neuropatholoy including Alzheimer's disease. Proc Nati Acad Sci USA 103(15): 5644-5651.
29. Mayeux R, Small SA, Tang M, et al. 2001. Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein-E. Neurobiol Aging 22(4): 683-689.
30. Monsch AU, Thalmann B, Schneitter M, et al. 2000. The Basel Study on the Elderly's search for preclinical cognitive markers of Alzheimer's disease. Neurobiol Aging 21: 31.
31. Nilsson LG, Nyberg L, Bäckman L. 2002. Genetic variation in memory functioning. Neurosci Biobehav Rev 26: 841-848.
32. O'Hara R, Yesavage JA, Kraemer HC, et al. 1998. The APOE ε4 allele is associated with decline on delayed recall performance in community-dwelling older adults. J Am Geriatr Soc 46: 1493-1498.
33. Saunders AM, Strittmatter WJ, Schmechel D, et al. 1993. Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43: 1467-1472.
34. Seeman TE, Huang M, Bretsky P, et al. 2005. Education and APOEe4 in Longitudinal Cognitive Decline: MacArthur Studies of Successful Aging. J Gerontol 60B: 74-83.
35. Small BJ, Fratiglioni L, Viitanen M, et al. 2000. The course of cognitive impairment in preclinical Alzheimer's disease: 3- and 6-year follow-up of a population-based sample. Arch Neurol 57: 839-844.
36. Small BJ, Rosnick CB, Fratiglioni L, Bäckman L. 2004. Apolipoprotein E and cognitive performance: a meta-analysis. Psychol Aging 19: 592-600.
37. Smith JD. 2002. Apolipoproteins and aging: emerging mechanisms. Ageing Res Rev 1: 345-365.
38. Smith CD, Andersen AH, Kryscio RJ, et al. 1999. Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease. Neurology 53: 1391-1396.
39. Smith GE, Bohac DL, Waring SC, et al. 1998. Apolipoprotein E genotype influences cognitive 'phenotype' in patients with Alzheimer's disease but not in healthy control subjects. Neurology 50: 355-362.
40. Stern Y, Brandt J, Albert M, et al. 1997. The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol 41: 615-620.
41. Thalmann B, Monsch AU, Schneitter M, et al. 2000. The CERAD neuropsychological assessment battery (CERAD-NAB) - a minimal dataset as a common tool for German-speaking Europe. Neurobiol Aging 21: 30.
42. Thalmann B, Spiegel R, Stähelin HB, et al. 2002. Dementia screening in general practice: Simplified scoring for the Clock Drawing Test. Brain Aging 2: 36-43.
43. Tilvis RS, Kähönen-Väre MH, Jolkkonen J, et al. 2004. Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontology Ser A: Biologic Sci Medic Sci 59: M268-M274.
44. Widmer LK, Stähelin HB, Nissen C, da Silva A. 1981. Venen-, Arterien-Krankheiten, Koronare Herzkrankheit bei Berufstätigen. Hans Huber: Bern.
45. Yip AG, Brayne C, Easton D, Rubinsztein DC. 2002. Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population. J Med Genet 39: 639-643.
46. Zehnder AE, Bläsi S, Berres M, et al. 2007. Lack of practice effects on neuropsychological as early cognitive markers of Alzheimer disease? Am J Alzheimers Dis Other Demen 22(5): 416-426.